A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs. City Therapeutics will develop its namesake cityRNAs—short for cleavage ...

“Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” said Governor Maura Healey, in a statement. “We are thrilled to see them ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. Biogen beat analysts’ revenue expectations by 1.2% last quarter, reporting ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Biogen Inc BIIB reported upbeat earnings for the third quarter on Wednesday. The company pisted third-quarter adjusted EPS of $4.08, down 6%, beating the consensus of $3.79. The company reported ...

At the meeting, Biogen will also host a virtual booth for attendees exploring the role of tau in Alzheimer’s disease, including an interactive medical education e-learning module on knowtau.com which ...

Biogen’s CEO may have been celebrating “turning a corner” last month, but it looks like the drugmaker’s early-stage pipeline hasn’t gotten the message yet. The Cambridge, Massachusetts ...

Biotechnology company Biogen is abandoning Aduhelm, its questionable Alzheimer's drug that has floundered on the market since its scandal-plagued regulatory approval in 2021 and brow-raising pricing.

Biogen's announcement On January 31 that it will discontinue development and commercialization of the anti-amyloid agent, aducanumab (Aduhelm), for Alzheimer's disease (AD) came as no surprise to ...

Biogen’s decision to move on from Aduhelm closes the book on what was once projected to be a major blockbuster drug, but it ended up the center of a controversy that eroded trust in the FDA’s ...